Biocardia says Japan filing work is progressing, FDA feedback on Helix is expected within six weeks, and a potential de novo submission is targeted for first quarter of 2027. It ended with $2.2 million in cash, providing runway into 2027.
BCDA · BioCardia, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Due to the factors described above, there is substantial doubt about our ability to continue as a going concern within one year after the date these financial statements are issued. While we believe in the viability of our strategy to raise additional funds, there can be no assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $0.77
- Open
- $0.79
- Day range
- $0.73–0.80
- 52-week closing range
- $0.77–1.47
- Average volume, 30 days
- 113K
- Short interest
- 735K · 4.9% of shares · 6.3 days
- Short volume, last session
- 80%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
BioCardia reported a $1.8 million net loss for the three months ended September 2026 and ended the quarter with $2.2 million in cash and cash equivalents, providing anticipated runway into 2027.
BioCardia reported $2.2 million in cash and cash equivalents, which management believes cannot fund planned expenditures and obligations beyond January 2027, raising substantial doubt about its ability to continue as a going concern.
BioCardia completed consultations with Japan's Pharmaceuticals and Medical Devices Agency (PMDA), advancing the CardiAMP Cell Therapy System toward a marketing approval application in Japan. Completion does not constitute regulatory approval, and PMDA review remains outstanding.
BioCardia announced the FDA accepted its De Novo pre-submission package for marketing clearance of the Helix catheter, with substantive review and a meeting expected this quarter.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. BioCardia advanced its Japan and Helix regulatory paths, reduced nine-month net loss, ended the quarter with cash providing runway into 2027, and continued expanding trial and imaging development. However, regulatory timing and funding remain risks, while Q3 net loss, nine-month operating cash use, and quarterly R&D expenses increased.
- + Biocardia answered PMDA's remaining questions to the agency's satisfaction and is proceeding with the Japan Shonin submission. new
- + If FDA supports the de novo pathway, BioCardia expects to complete the Helix submission in the first quarter of 2027 and receive approval in mid-2027. new
- + Nine-month net loss decreased to $5.7 million from $6.2 million, primarily due to lower research and development expenses. new
- + The CardiAMP Heart Failure II trial has four actively recruiting sites, seven additional sites are being onboarded, and management is aware of no safety issues. new
- + BioCardia ended the quarter with $2.2 million of cash and cash equivalents, providing anticipated runway into 2027. new
- + BioCardia is working with CART-Tech to advance the Heart3D platform into the clinic in 2027. new
- − The Japan submission timeline faces a risk that product documentation may require additional testing or work. new
- − BioCardia may need further discussions with FDA if the agency does not support the Helix de novo approval pathway. new
- − Q3 net loss increased to $1.8 million from $1.5 million. new
- − Net cash used in operations for the first nine months increased to $5.1 million from $4.9 million. new
- − Q3 research and development expenses increased to $1.2 million from $0.9 million. new
- − BioCardia faces the risk of being unable to raise additional funding needed to continue its product development plans. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net cash used in operations | $5.1M | nine months ended September 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCDA
this stock
BioCardia, Inc.
|
$11.70M | -38.2% | -16.8% | — | 4.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 32
BioCardia reported $2.2 million in cash and cash equivalents, which management believes cannot fund planned expenditures and obligations beyond January 2027, raising substantial doubt about its ability to continue as a going concern.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCDA | -6.5% | -16.8% | -16.0% | -10.3% | -38.2% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -1.0% | -10.5% | -10.4% | -5.0% | -43.2% |